Should I buy Humana (HUM) stock or is it too late?

Humana · Health Care · price $393

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $370 (-5.8 %), call made on August 6, 2026, maturing on August 6, 2027 (22 d ago).

The 10 reliable analysts $399+1.7 %

The 5 other firms $415+5.7 %

How to read it: the 10 reliable firms are not filtered by optimism — 6 aim above the price, 4 below, hence their $399 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Humana

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
JP Morgan	77 %	+18.9 %	13	$393 +0%
Barclays	67 %	+17.1 %	6	$407 +4%
Jefferies	64 %	+14.2 %	14	$235 -40%
Morgan Stanley	62 %	+11.9 %	21	$370 -6%
Wells Fargo	70 %	+10.9 %	10	$502 +28%
Piper Sandler	40 %	+4.7 %	5	$254 -35%
Mizuho	38 %	+0.6 %	8	$390 -1%
RBC Capital	29 %	-10.5 %	17	$415 +6%

In short — Should you invest in Humana? Is it too late, still worth it? Analysts are split (31% buy, median target $405, i.e. +3%), and the most reliable on HUM targets even higher. But the valuation is stretched (P/E ~37). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on HUM, JP Morgan (77% hit rate, 13 scored calls), targets $393 (call made on August 10, 2026, maturing on August 10, 2027) (+0%) in its most recent call, and $214 (call made on May 1, 2026, maturing on May 1, 2027) (-45%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 16 ratings, 11 are neutral.
Limited upside: the median target is only +3% from the current price.
High valuation (P/E ~37): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on HUM

Median target $405 (+3%) · 16 ratings · Hold consensus

Strong Buy00%

Buy531%

Hold1169%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Humana now?

We won't decide for you. The facts: 31% of analysts rate it a buy, median target $405 (+3%), and JP Morgan (most reliable on HUM, 77%) targets $393. Weigh that against valuation (P/E ~37). This is not personalized advice.

Is it too late to invest in Humana?

The stated upside is small: the median target ($405) sits just +3% from the price ($393) (most reliable on HUM: JP Morgan, 77%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Humana still worth investing in?

It depends on the gap between the price ($393) and its estimated value: analysts target $405 on median (+3%), with 31% buys (most reliable on HUM: JP Morgan, 77%). Cross-check with their real reliability on HUM and the cautions above. Information, not advice.

What's the main risk in buying HUM?

The consensus is not unanimous: of 16 ratings, 11 are neutral.

→ Go deeper: the full Humana profile (consensus, analyst reliability, price target, performance).